Support By : Li-lab
PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
---|---|---|---|---|---|
Hedgehog signaling pathway | R-HSA-5358351 | map04340 | triflupromazine | 5568 | drug-path |
Long-term potentiation | R-HSA-9620244 | map04720 | triflupromazine | 5568 | drug-path |
Chemokine signaling pathway | R-HSA-168638 | map04062 | triflupromazine | 5568 | drug-path |
Gap junction | R-HSA-190861 | map04540 | triflupromazine | 5568 | drug-path |
Calcium signaling pathway | R-HSA-381753 | map04020 | triflupromazine | 5568 | drug-path |
Amyotrophic lateral sclerosis (ALS) | Q8NDH6-2 | 0 | Prestwick-1100 | None | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | Prestwick-1100 | None | drug-path |
Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | Prestwick-1100 | None | drug-path |
Calcium signaling pathway | R-HSA-381753 | map04020 | Prestwick-1100 | None | drug-path |
ECM-receptor interaction | R-HSA-373711 | map04512 | phenazone | 5342 | drug-path |
Glioma | Q9NZM4 | map05214 | diflunisal | 3059 | drug-path |
B cell receptor signaling pathway | R-HSA-983705 | map04662 | diflunisal | 3059 | drug-path |
T cell receptor signaling pathway | R-HSA-983705 | map04660 | diflunisal | 3059 | drug-path |
Systemic lupus erythematosus | R-HSA-977105 | map05322 | diflunisal | 3059 | drug-path |
Pancreatic cancer | R-HSA-9700206 | map05212 | diflunisal | 3059 | drug-path |
Prostate cancer | R-HSA-2990872 | map05215 | diflunisal | 3059 | drug-path |
Acute myeloid leukemia | R-HSA-9680350 | map05221 | diflunisal | 3059 | drug-path |
Bladder cancer | R-HSA-9700206 | map05219 | diflunisal | 3059 | drug-path |
Melanoma | Q9UHD0-PRO_0000015379 | map05218 | diflunisal | 3059 | drug-path |
Non-small cell lung cancer | R-HSA-5619066 | map05223 | diflunisal | 3059 | drug-path |